Mode of transmisison: droplet - one of most infectious!; R0 = 12-18 in developed countries
Incubation: 10d: maybe 7-18d from exposure to onset of fever
Period of infectivity: 5d before to 5d after rash onset - day of rash onset = d1
Vaccines: live attenuated vaccine
MMR
egg allergy NOT contraindicaiton
Schedule: 15mo and 4yr
efficacy: very effective
Herd: need 95% immunisation
-
RNA virus
-
humans = only natural host
clinical
-
prodromal phase of 2-4days with:
-
fever
-
3 C’s
-
cough
-
conjunctivitis
-
coryza
-
-
Koplik’s spots
-
-
maculopapular rash
-
first behind ears on 3-7d
-
speads over from head and face -> trunk
-
-
convalescnet stage
- temporary brownish stain on skin
-
complications
-
AOM
-
pneumonia
-
croup
-
diarrhoea
-
encephalitis:
-
1:1000
-
15% die
-
25-35% left with permanent neurological damage
-
-
-
sub-acute sclerosing panencephalitis
-
fatal
-
typcially 7-10yrs after wild type measles virus infection
-
-
-
vitamin a associated with dec mortality/morbidity
-
od for 2d at:
-
200 000IU ≥12mo
-
100 000 IU 6-11mo
-
50 000 IU \<6mo
-
-
Expected response
-
fever >39.4 in 5-15%
-
lasts 1-2d
-
rash 5%: 6-12d after immunisation
-
most causes unrelated to immunisation
-
mumps:; parotid and/or submaxillary swelling
-
rubella; mild rash, fever, lymphadenopathy 2-4wl
-
febrile seizures 1:3000 6-12d after immunisation
-
increased fisk of ITP
During outbreak
-
MMR can be given to unvaccinated people, who are not immunocompromised, within 72h of exposure - this may prevent infection
-
lahtough immune response may not be very effective; can be given 6-12mo if being reported in young children
-
still require 2 doses
-
-
Human normal immunoglobulin
-
CI to MMR
-
immunocompromised children and adults
-
pregnant women
-
children \<15mo and >72hrs post exposure
-
>82hrs exposre no history or no MMR
-
given ASAP after eposure
-
can be given up to 6d
-
not within 3wk of live virurs
-
live virus not 11mo after
-
-
-
IVIG - Intragam P
-
IV compared to IM
-
immunocompromised
-